Efgartigimod
argenx
['ct041']
and we keep going with data from the advance iv phase 3 trial reporting on efficacy and safety of efgartigimod in adults with primary immune thrombocytopenia: #ash22 
MD @ClevelandClinic @unitorvergata | Lymphoma survivor#Resilient | MDS/AML/APL/Bone marrow failure syndromes| Member @TheEBMT_Trainee | Opinions are my own